Skip to content
The Policy VaultThe Policy Vault

lenalidomide — Medica

Chronic lymphocytic leukemia

Initial criteria

  • age ≥ 18 years
  • Relapsed or refractory disease
  • Patient has tried at least one Bruton-tyrosine kinase inhibitor

Approval duration

1 year